| __timestamp | Alnylam Pharmaceuticals, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 17763000 |
| Thursday, January 1, 2015 | 60610000 | 22180000 |
| Friday, January 1, 2016 | 89354000 | 37257000 |
| Sunday, January 1, 2017 | 199365000 | 27367000 |
| Monday, January 1, 2018 | 382359000 | 64770000 |
| Tuesday, January 1, 2019 | 479005000 | 74986000 |
| Wednesday, January 1, 2020 | 588420000 | 79256000 |
| Friday, January 1, 2021 | 620639000 | 100156000 |
| Saturday, January 1, 2022 | 770658000 | 131408000 |
| Sunday, January 1, 2023 | 795646000 | 152946000 |
| Monday, January 1, 2024 | 975526000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, Alnylam Pharmaceuticals, Inc. and Dynavax Technologies Corporation have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. Since 2014, Alnylam's SG&A expenses have surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Dynavax has experienced a more modest increase of approximately 760%, indicating a more conservative growth strategy.
By 2023, Alnylam's SG&A expenses reached nearly 800 million, dwarfing Dynavax's 153 million. This disparity highlights Alnylam's commitment to scaling its operations, possibly to support its innovative RNAi therapeutics. Meanwhile, Dynavax's steadier growth may suggest a focus on optimizing existing resources. These trends offer a glimpse into the strategic priorities of these companies as they navigate the evolving biotech industry.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Mesoblast Limited
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation